Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN versus NATACYN.
GRISACTIN vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic